GSK’s better-than-expected results overshadowed by Zantac litigation
The British pharmaceutical giant beat expectations but saw its share price drop on investors’ concerns about lawsuits surrounding its Zantac heartburn medicine
It’s rescued investors in the past from a lost decade
‘There’s this debate between a hard landing, a soft landing or no landing that continues,’ says Lerner at Truist Advisory...
Many 5% CDs are going away in the weeks after the Fed’s first interest-rate cut. Some have already disappeared.
Some analysts warn the pool of potential gold buyers could begin to run dry.
September has historically been the worst month for U.S. stocks — but not this year
Homeowners looking to leverage lower mortgage rates can ask their lenders for a “rate modification,” financial experts say.